The following stories appear in full on Today's Vidyya Medical News Service Web site.
Radiant Medical, Inc. announced the world's first treatment of a heart attack patient with cool therapy. The patient was enrolled in an ongoing clinical trial, COOL MI, designed to investigate the feasibility of cool therapy in heart attack patients. The experimental procedure is intended to reduce the injury caused by a heart attack by reducing the heart's need for oxygen and preventing cell death.
For more information: Cool Therapy Used To Treat Myocardial Infarction
Occasionally, Vidyya comes across an item of controversy that seems like something in which our readers might have an interest. This is the case with http://www.watercure.com, where according to F. Batmanghelidj, MD, the cause of much pain and suffering is dehydration. According to Dr. Batmanghelidj, dehydration is at the root of a host of conditions from hypertension to lupus. Fact or fiction? We at Vidyya don't know, but we thought our readers might like to make up their own minds.
For more information: The Water Cure: Bad Medicine Or Miracle?
Purple grape juice appears unique in its potential ability to provide a beneficial effect to a variety of cardiovascular functions. According to preliminary research by a University of Scranton professor, the fruit of the grapevine appears to bear powerful antioxidant qualities that may improve the body's healthy cardiovascular function.
For more information: The Power Of Grape Juice
The Endometriosis Association is launching a series of new campaigns to educate the public, health care providers and the news media. The cornerstone of the new programs will be free, year-round physician screenings for endometriosis.
For more information: March Is Endometriosis Awareness Month
The February issue of Urology, a respected peer-reviewed specialty journal, carries a paper detailing a successful Phase 2 study demonstrating the safety and efficacy of Topiglan®, MachroChem's topical drug for erectile dysfunction (ED). The company has filed the results of this study with the U.S. Food & Drug Administration, and is now in a phase 3 pivotal trial to support an application for marketing approval.
For more information: Topical Cream For Erectile Dysfunction Successfully Completes Phase II Clinical Studies
Today's Vidyya articles are:
As always, we hope you enjoy the issue.